Abstract 1647: CC2000199, a potent and selective androgen receptor ligand-directed degrader (AR LDD) with a dual mechanism of action, exhibits anti-tumor activity in multiple enzalutamide-resistant preclinical models for metastatic castration-resistant prostate cancer
Year: 2025
Type: conference-abstract
Source: Cancer Research
Authors: Surendra Nayak, Massimo Ammirante, Emily Rychak, Debbie Liao, John D. Norris, Suzanne E. Wardell, Shailaja Kasibhatla, Veronique Plantevin-Krenitsky, Evan Horn, Joseph R. Piccotti, Stephen Norris, Raju Kandimalla, Joseph Meiring, Samantha Reiss, Joshua M. Baughman, Marwa Khater, Deborah S. Mortensen, Brian Cathers, Neil Bence, Daniel W. Pierce, Joshua D. Hansen, Lawrence G. Hamann, Donald P. McDonnell, Rama K. Narla, Mark Rolfe, Shuichan Xu
Institutions: Bristol-Myers Squibb (United States), Duke University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4409624371